Third Annual Therapeutic Advances in the Treatment of Hematological Malignancies

Last Modified: May 25, 2005

Conference Dates: August 3-6, 2005
Conference Location: Santa Monica, California

Sponsoring Group: The CBCE

Conference Web Page URL:

Topics Covered: Description/Statement of Need: Typically, hematologic malignancies are sensitive to chemotherapy and radiation therapy, but a significant proportion of patients are not cured with traditional treatments. Chemotherapy resistance leads to a pattern of relapse and retreatment, driving the need for improved therapies that increase complete response rates, extend response durations, and eliminate residual disease. Tyrosine kinase inhibitors, such as imatinib, have provided impressive activity in chronic myelogenous leukemia (CML), but resistance to these novel agents is still an issue. In addition, recent data has highlighted the importance of prognostic indicators in the treatment of hematologic malignancies. Patient selection based on these indicators allows physicians to identify and promptly treat patients at the highest risk of rapidly progressive disease. This program will update physicians on the latest advances in the treatment and diagnosis of hematologic malignancies with emphasis on optimizing patient clinical outcome through the use of novel regimens, schedules, and diagnostic techniques.

Conference Objectives: Please see website for further information.

Who Should Attend: This activity is intended for medical oncologists, hematologists, and other health care professionals who treat patients with hematological malignancies.

Conference Agenda: Educational Objectives: After participating in this conference, attendees should be able to:

  1. Describe recent efforts to optimize the efficacy of tyrosine kinase inhibitors in the treatment of CML.
  2. Assess the results of studies investigating the use of molecular markers as prognostic and predictive indicators of response for patients with acute myeloid leukemia.
  3. Compare the efficacy of therapeutic regimens currently being tested for the treatment of minimal residual disease in patients with chronic lymphocytic leukemia, and evaluate the overall effect of these agents on patient outcome.
  4. Evaluate recent clinical trials investigating the use of novel therapeutic agents for the treatment of imatinib-resistant CML.
  5. Describe the rationale for the use of mTOR inhibitors in the treatment of acute lymphoblastic leukemia.

Registration Information: Registration Website:

*A limited number of Scholarships are available for fellows. For consideration and further information, please contact Zack Lentz.

Conference Fees: Please see website for further information.

Continuing Education: Yes

Miscellany: This activity has been approved for AMA Physician’s Recognition Award credits. AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by ACCME.